Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects
Atrial Fibrillation, Atrial Flutter
About this trial
This is an interventional treatment trial for Atrial Fibrillation focused on measuring Atrial fibrillation, atrial flutter, anti-arrhythmic agents, conversion to normal sinus rhythm
Eligibility Criteria
Inclusion Criteria: Willing to sign informed consent before screening examinations are performed and before the study drug is administered Females > 18 years of age Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration > 3 hours and < 45 days) at the time of randomization Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure > 90 mmHg and diastolic blood pressure < 105 mmHg) Exclusion Criteria: Pregnancy and lactation Acute myocardial infarction and cerebrovascular accidents Coronary syndromes and congestive heart failure (CHF) New York Heart Association (NYHA) IV Life-threatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities Concurrent antiarrhythmic treatments
Sites / Locations
- Site 26
- Site 27
- Site 5
- Site 2
- Site 3
- Site 4
- Site 6
- Site 7
- Site 8
- Site 11
- Site 12
- Site 14
- Site 15
- Site 9
- Site 13
- Site 10
- Site 16
- Site 22
- Site 20
- Site 25
- Site 19
- Site 18
- Site 24
- Site 17
- Site 23
- Site 21